Estudio de calidad biofarmacéutica de los fármacos de forma farmacéutica sólida utilizados como alternativas terapéuticas para la covid-19

Abstract

COVID-19 disease caused by SARS-CoV-2 virus is native to Wuhan, China, in December 2019, which causes respiratory diseases, raining from mild or even fatal symptoms. Because of this, one of the biggest health problems was finding therapeutic alternatives that help combat symptoms and lower the COVID-19 mortality rate. Various drugs in a solid pharmaceutical form have been used to help improve the patient, for this reason, they underwent various clinical studies to help demonstrate the safety and efficacy of counteracting the viral load. This work aims to demonstrate through a bibliographic review, that drugs in a solid pharmaceutical form used as therapeutic alternatives for COVID-19, comply with biopharmaceutical quality parameters. Among the solid pharmaceutical drug quality assays are the parameters of friability, hardness, content uniformity, disintegration and dissolution, which allow to determine their technological quality prior to their approval for commercialization. On the other hand, bioequivalence studies were revised in vitro such as the dissolution profile and in vivo trials such as relative bioavailability in magnitude and speed by comparing the test drug with the reference drug, which ensures its effectiveness and efficiency in determining pharmaceutical interchangeability. Finally, the drugs in a solid pharmaceutical form reviewed, if they meet the biopharmaceutical quality parameters, so it is concluded that they are pharmaceutical equivalents.